Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models

被引：4
|
作者：
Yin, L. [1 ]
Yao, Z. [1 ]
Wang, Y. [2 ]
Huang, Y-H. [3 ]
Mazuranic, M. [4 ]
Yin, A. [5 ]
机构：
[1] Gan & Lee Pharmaceut, R&D Dept, Beijing, Peoples R China
[2] Gan & Lee Pharmaceut USA Corp, Global Nonclin Sci, Bridgewater, NJ USA
[3] Gan & Lee Pharmaceut USA Corp, Global Clin Sci, Bridgewater, NJ USA
[4] Gan & Lee Pharmaceut USA Corp, Global Med Affairs, Bridgewater, NJ USA
[5] Gan & Lee Pharmaceut, Domest Clin Dev Dept, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4MO
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [1] PRECLINICAL EVALUATION OF NOVEL CDK4/6 INHIBITOR GLR2007 IN GLIOBLASTOMA MODELS
    Yin, Lei
    Yao, Zhenglin
    Wang, Yue
    Huang, Ying-Hui
    Mazuranic, Michelle
    Yin, Ang
    NEURO-ONCOLOGY, 2021, 23 : 166 - 166
  • [2] Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in glioblastoma models.
    Yin, Lei
    Yao, Zhenglin
    Wang, Yue
    Huang, Julius
    Mazuranic, Michelle
    Yin, Ang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Preclinical evaluation of CDK4/6 inhibitor and biomarker exploration in gastric cancer
    Bae, Hyun Joo
    Kwon, Woo Sun
    Kim, Hyun Jeong
    Kang, Sun Kyoung
    Jeong, Inhye
    Kim, Tae Soo
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Clinical development of CDK4/6 inhibitor for breast cancer
    Iwata, Hiroji
    BREAST CANCER, 2018, 25 (04) : 402 - 406
  • [5] Clinical development of CDK4/6 inhibitor for breast cancer
    Hiroji Iwata
    Breast Cancer, 2018, 25 : 402 - 406
  • [6] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
    Martin, Miguel
    Garcia-Saenz, Jose A.
    Manso, Luis
    Llombart, Antonio
    Cassinello, Alejo
    Atienza, Manuel
    Ringeisen, Francois
    Ciruelos, Eva
    FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
  • [7] Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer
    Lim, Elgene
    Portman, Neil
    Alexandrou, Sarah
    Haupt, Susan
    Haupt, Ygal
    Caldon, Elizabeth
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer
    Palumbo, Alison
    Lau, Gary
    Saraceni, Megan
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 178 - 185
  • [9] Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Li, Zhen
    Zou, Wei
    Zhang, Ji
    Zhang, Yunjiao
    Xu, Qi
    Li, Siyuan
    Chen, Ceshi
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [10] Preclinical head-to-head comparison of CDK4/6 inhibitor activity toward CDK4 vs CDK6
    Delach, Scott
    Caponigro, Giordano
    CANCER RESEARCH, 2021, 81 (04)
12345